Improved graft survival after renal transplantation in the United States, 1988 to 1996

New England Journal of Medicine

Volumn 342, Issue 9, 2000, Pages 605-612

  Hariharan, Sundaram ^a   Johnson, Christopher P ^a   Bresnahan, Barbara A ^a   Taranto, Sarah E ^b   McIntosh, Matthew J ^c   Stablein, Donald ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNITED NETWORK FOR ORGAN SHARING   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLOSPORIN; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ANTIBODY TITER; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; DEMOGRAPHY; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HALF LIFE TIME; HLA MATCHING; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; UNITED STATES;

ADULT; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 0034594881     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003023420901     Document Type: Article

References (31)

1. Renal Data System. USRDS 1998 annual data report. Bethesda, Md.: National Institute of Diabetes and Digestive Kidney Diseases, April 1998: 39. (NIH publication no. 98-3176.)
2. Hariharan S, McBride MA, Bennett LE, Cohen EP. Risk factors for renal allograft survival from older cadaver donors. Transplantation 1997;64: 1748-54.
3. Merion RM, White DJG, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984;310:148-54.
4. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. M Engl J Med 1985;313:337-42.
5. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-32.
6. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-83.
7. Thiel G, Bock A, Spondlin M, et al. Long-term benefits and risks of cyclosporin A (sandimmun): an analysis at 10 years. Transplant Proc 1994; 26:2493-8.
8. Valente JF, Hariharan S, Peddi VR, et al. Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era. Clin Transplant 1997;11:231-6.
9. Jindal RM, Hariharan S. Chronic rejection in kidney transplants: an indepth review. Nephron 1999;83:13-24.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
11. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955;34:327-82.
12. Hariharan S, Alexander JW, Schroeder TJ, First MR. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. Clin Transplant 1996;10:186-90.
13. Tejani A, Cortes L, Stablein D. Clinical correlates of chronic rejection in pediatric renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996;61:1054-8.
14. Sumrani N, Cacciarelli TV, Georgi B, et al. Contribution of acute rejection to renal allograft loss from chronic rejection. Transplant Proc 1993; 25:2259-60.
15. Cosio FG, Pelletier RP, Falkenhain ME, et al. Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997;63:1611-5.
16. Hariharan S, Alexander JW, Schroeder TJ, First MR. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. Clin Transplant 1996;10:538-41.
17. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752-7.
18. Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM. Predictions of long-term primary cadaveric renal transplant survival. Clin Transplant 1993;7:345-52.
19. Rush DN, Jeftery JR, Gough J. Sequential protocol biopsies in renal transplant patients: clinico-pathological correlations using the Banff schema. Transplantation 1995;59:511-4.
20. Rush DN, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9:2129-34.
21. Kasiske BL, Neylan JF III, Riggio RR, et al. The effect of race on access and outcome in transplantation. N Engl J Med 1991;324:302-7.
22. Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences in black versus white recipients. Transplantation 1991;53:338-42.
23. Hariharan S, Schroeder TJ, First MR. Effect of race on renal transplant outcome. Clin Transplant 1993;7:235-9.
24. Burke JF Jr, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994;331: 358-63.
25. Morris PJ. Factors influencing outcome in cadaveric renal transplantation. Br J Surg 1994;81:635-6.
26. Cole E, Naimark D, Aprile M, et al. An analysis of predictors of long-term cadaveric renal allograft survival. Clin Transplant 1995;9:282-8.
27. Paul LC. Chronic renal transplant loss. Kidney Int 1995;47:1491-9.
28. Alexander JW, Bennett LE, Breen TJ. Effect of donor age on outcome of kidney transplantation: a two-year analysis of transplants reported to the United Network for Organ Sharing Registry. Transplantation 1994;57:871-6.
29. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999;34: 296-303.
30. Tejani A, Sullivan EK. Higher maintenance cyclosporine dose decreas es the risk of graft failure in North American children: a report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1996;7:550-5.
31. Schroeder TJ, Hariharan S, First MR. Variation in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant Proc 1995;27:837-9.